The 63 year old chairman of a listed company has filed an investigation, and the Central Commission for Discipline Inspection has shown its sword! Concentrated rectification of the pharmaceutical industry in the field of biology | Chairman | Listed company
On the evening of July 30th, the antivenom serum pharmaceutical company Salon Biotech announced that its chairman had been detained and filed for investigation.
Announcement shows that on July 29, 2023, Fan Zhihe, one of the actual controllers, chairman, and legal representative of Sailun Biotechnology, received the "Notice of Detention" and "Notice of Filing" issued by the Shanghai Municipal Supervision Commission. Fan Zhihe was detained and investigated for suspected crimes committed by his position.
Sailun Biotechnology is a company listed on the Science and Technology Innovation Board on March 11, 2022. The company mainly engages in the research, development, production, and sales of anti serum and anti toxin drugs.
Prior to that, Salon Biological was once concerned because of its status as a "COVID-19 Concept Unit".
![The 63 year old chairman of a listed company has filed an investigation, and the Central Commission for Discipline Inspection has shown its sword! Concentrated rectification of the pharmaceutical industry in the field of biology | Chairman | Listed company](https://a5qu.com/upload/images/c0d6c9ee33419d0b9cc613826059b1d7.jpg)
The 2022 annual report shows that at the end of the reporting period, the company decided to terminate the research and development of two projects, namely, anti novel coronavirus immunoglobulin 2) and anti tetanus bivalent and multivalent monoclonal antibodies, after careful consideration of the progress of research and development projects, changes in the competitive pattern, subsequent development risks and future expectations.
According to the 2022 annual report of Sailun Biotechnology, Fan Zhihe, his wife Zhao Aixian, and son Fan Tiejiong are concerted actors, jointly holding 56.23% of the equity of Sailun Biotechnology.
As the head of the private enterprise Sailun Biotechnology, Fan Zhihe was detained and investigated by the Shanghai Municipal Supervision Commission. What would be the reason for this?
Yang Cheng, a lawyer at Beijing Long'an Law Firm, analyzed to First Financial reporters that Fan Zhihe may be suspected of bribery, introduction bribery, or joint duty crimes. Fan Zhihe's department under investigation this time is the supervisory authority, and it is currently impossible to determine from public information that he belongs to the supervision objects referred to in the Supervision Law and the Implementation Regulations of the Supervision Law. According to Article 46, Paragraph 4 of the Implementation Regulations of the Supervision Law, the supervisory authority can investigate cases of suspected public officials committing crimes by taking advantage of their official duties, and may, in accordance with the law, have jurisdiction over non public officials involved in suspected bribery, bribery, or joint official crimes. In a broad sense, all individuals related to the case can be referred to as the involved individuals, including those under investigation and bribery, as well as other individuals who assist or participate in the commission of disciplinary or official violations, victims, witnesses, etc.
![The 63 year old chairman of a listed company has filed an investigation, and the Central Commission for Discipline Inspection has shown its sword! Concentrated rectification of the pharmaceutical industry in the field of biology | Chairman | Listed company](https://a5qu.com/upload/images/d86d13f9aea864fd09f5bc4a19584be4.jpg)
It is worth mentioning that before the detention of the Chairman of Sailun Biotechnology, Zhou Wei, the actual controller and Chairman of Weining Health, a medical software development enterprise, was also detained by the Supervision Committee of Maoming City, Guangdong on July 1. On July 5th, Weining Health responded that Zhou Wei was investigated and detained on suspicion of bribery.
Currently, the anti-corruption efforts in the pharmaceutical industry are being strengthened. This month, the National Health Commission, together with the Ministry of Education, the Ministry of Public Security and other departments, jointly held a video conference to deploy a one-year nationwide campaign to address corruption in the pharmaceutical industry. The meeting emphasized that in response to the key links and "key minorities" in the pharmaceutical industry, such as production, supply, sales, use, and reimbursement, we will adhere to a combination of addressing both symptoms and root causes, and implement strict and lenient measures. We will deepen the systematic governance of the pharmaceutical industry across all fields, chains, and covers, further forming a high-pressure situation and promoting the integration of "not daring to corrupt, not being corrupt, and not wanting to corrupt".
Subsequently, the Central Commission for Discipline Inspection and the National Supervisory Commission also held a mobilization meeting, deploying disciplinary inspection and supervision agencies to cooperate in carrying out centralized rectification of corruption in the national pharmaceutical industry.